Literature DB >> 11049732

NGF over-expression during development leads to permanent alterations in innervation in the spinal cord and in behavioural responses to sensory stimuli.

A Ribeiro-da-Silva1, A C Cuello, J L Henry.   

Abstract

Transgenic mice expressing nerve growth factor (NGF) under the control of a myelin basic protein promoter display above normal NGF levels in the spinal white matter from birth to the age of 2 months. These transient high levels of NGF result in a lasting hyper-innervation of the spinal white matter by ectopic Substance P (SP)-immunoreactive (IR) sensory fibres. Ultrastructural studies in adult transgenic mice demonstrated that the SP-containing fibres establish synapses on neuronal dendrites in the white matter and that most such dendrites express SP receptors. The transgenic animals display a stimulus-induced hyperalgesia and allodynia in a test measuring the latency to tail withdrawal following a heat stimulus. The hyperalgesia and allodynia were reversed by systemic administration of SP receptor or NMDA receptor antagonists. Surprisingly, the application of morphine resulted in an increase in withdrawal latency which was greater than that observed in non-transgenic controls. Copyright 2000 Harcourt Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11049732     DOI: 10.1054/npep.2000.0822

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  2 in total

1.  Time course of substance P expression in dorsal root ganglia following complete spinal nerve transection.

Authors:  Wendy Weissner; Barbara J Winterson; Alan Stuart-Tilley; Marshall Devor; Geoffrey M Bove
Journal:  J Comp Neurol       Date:  2006-07-01       Impact factor: 3.215

2.  Accelerated onset of the vesicovesical reflex in postnatal NGF-OE mice and the role of neuropeptides.

Authors:  Beatrice Girard; Abbey Peterson; Susan Malley; Margaret A Vizzard
Journal:  Exp Neurol       Date:  2016-06-21       Impact factor: 5.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.